The FDA today posted a warning letter sent to LeMaitre (LMAT), dated August 11, following an inspection of the company’s North Brunswick, New Jersey facility. The inspection revealed that LeMaitre’s Artegraft collagen vascular grafts are adulterated. Shares of LeMaitre closed Tuesday down 2% to $95.28.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMAT: